Adapting to new standards of training for physicians has been difficult across specialties. But Calvin Brown Jr., MD, says that by investing time and patience to understand the big picture, rheumatologists will benefit from the Accreditation Council for Graduate Medical Education’s Next Accreditation System…
Search results for: Big data
From the Expert: New Advances in Treatment of Systemic Scleroderma
A recent study found that mycophenolate mofetil is an effective alternative for the treatment of systemic scleroderma with interstitial lung disease, resulting in possible long-term improvement. According to Aryeh Fischer, MD, this new research points to the future expansion of treatment options…
2015 ACR/ARHP Annual Meeting: Global Challenges in Rheumatic Disease Care
SAN FRANCISCO—To convey the plight of rheumatology patients in sub-Saharan Africa, Girish Mody, MD, head of rheumatology at the University of KwaZulu-Natal in South Africa and past president of the African League of Associations for Rheumatology, recounted a story during the 2015 ACR/ARHP Annual Meeting from the World Health Organization about a diabetes patient. The…
The Microbiome in Pediatric Rheumatic Diseases
The human intestinal microbiota is home to more than 1,000 bacterial species, containing approximately 3 million genes, many of which code for functions that have the potential to affect human physiology.1 Smaller numbers of organisms are also present in the skin, upper gastrointestinal tract, female reproductive tract and the oro- and nasopharynx. As tools have…
Medicare Access and CHIP Reauthorization Act of 2015: What You Should Know
There is no denying that the past few years have been a time of immense change in healthcare. Sweeping pieces of legislation have fundamentally altered the way we practice medicine. This is absolutely the case when it comes to the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA, for short). MACRA is an enormous…
Opinion: Politics Should Not Trump Science in Medicine
I tell my patients there are three types of science: 1) investigative science, which sometimes gets it right; 2) science in the courtroom, which is junk science; and 3) science in Washington, D.C., which is political science. Our decisions are based on art and science; our patients’ medications are brought to market based on science….
Biosimilars Debate Heats up over Cost Savings, Safety Concerns
After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…
Diagnosis Can Be Elusive for Fever of Unknown Origin
Settling into room 501 at Maine Medical Center, Mrs. N was on her way to the bathroom when she felt it coming on. One moment she was okay; the next, her chest felt damp and cold, even as her face flushed and her temperature spiked. Her forehead glistened beads of warm sweat. She felt the…
2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis
SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…
Rheumatology Research Foundation-Funded Study Shows Promise for New RA Treatments
Joseph Holoshitz, MD, and his laboratory have made significant advances in understanding a genetic risk factor of rheumatoid arthritis (RA). This knowledge has grown into discoveries that could lead to new RA treatments in just a few years. “There was a critical point in time when we had a big idea, but funding was a…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 51
- Next Page »